Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; ACh, acetylcholine; AChE, acetylcholinesterase; AD, Alzheimer’s disease; ANOVA, analysis of Variance; Aβ, amyloid-beta; BSA, bovine serum albumin; Caffeic acid, 3,4-dihydroxycinnamic acid; DMSO, dimethylsulfoxide; DNPH, 2,4-dini
مقالات ISI 6-OHDA، 6-hydroxydopamine (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; 2-AG, 2-arachidonoylglycerol; BDNF, brain derived neurotrophic factor; CB1, cannabinoid receptor type 1; Cg, cingulate cortex; CNS, central nervous system; CO2, carbon dioxide; Cpudl, caudate putamen dorsolateral; Cpum, caudate
Keywords: 6-OHDA، 6-hydroxydopamine; LA, low anxiety; HA, high anxiety; 6-OHDA, 6-hydroxydopamine; EPM, elevated plus maze; MFB, medial forebrain bundle; OFT, open field test; PD, Parkinson’s disease; SNc, substantia nigra compactaAnxiolytic; Parkinson’s disease; Non-motor symptom; Elevated
Keywords: 6-OHDA، 6-hydroxydopamine; α-Syn, α-synuclein; 3-MT, 3-methoxytyramine; 6-OHDA, 6-hydroxydopamine; Ach, acetylcholine; ANOVA, analysis of variance; COMT, catechol-O-methyltransferase; DA, dopamine; DAT, dopamine transporter; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanilic a
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; ABP, actin binding protein; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; APP, amyloid precursor protein; Aβ, amyloid-β; Cdk5, cyclin-dependent kinase 5; CMT, Charcot-Marie-Tooth disease; CMT2, Charcot-Marie-Tooth
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; BCIP, 5-bromo-4-chloro-3-indolyl phosphate; COX-2, cyclooxygenase-2; DTNB, 5,5-Dithiobis 2-Nitrobenzoic acid; ETC, electron transport chain; GFAP, glial fibrillary acidic protein; HSP, heat shock proteins; HSF-1, heat shock fact
Keywords: 6-OHDA، 6-hydroxydopamine; 5-HIAA, 5-hydroxyindoleacetic acid; 6-OHDA, 6-hydroxydopamine; DA, dopamine; DOPAC, 3–4-dihydroxyphenylacetic acid; EDTA, ethylenediaminetetraacetic acid; FFT, fast Fourier transform; H2O2, hydrogen peroxide; HPLC, high-performance liquid chromatography;
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; AIMs, abnormal involuntary movements; AMPA, 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid; DA, dopamine; DBS, deep brain stimulation; ERK1/2, extracellular signal-regulated kinase 1/2; GPe, external globus pallidus;
Keywords: 6-OHDA، 6-hydroxydopamine; Angiotensin; Candesartan; l-DOPA; Neuroprotection; Parkinson; Serotonin5-HIAA, metabolite 5-hydroxyindolacetic acid; 5-HT, serotonin; 6-OHDA, 6-hydroxydopamine; AII, angiotensin II; AT1, angiotensin type-1 receptor; AT2, angiotensin type-2 receptor; AUC,
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; ADH, alcohol dehydrogenase; ALDH, acetaldehyde dehydrogenase; BAC, blood alcohol concentration; BAES, Biphasic Alcohol Effects Scale; B-BAES, Brief Biphasic Alcohol Effects Scale; BXD RI, recombinant inbred mice; COF, consume of
Keywords: 6-OHDA، 6-hydroxydopamine; PD, Parkinson’s disease; DA, dopamine; 6-OHDA, 6-hydroxydopamine; PGC-1α, peroxisome proliferator-activated receptor-γ coactivator 1α; AMPK, AMP-activated protein kinase; pAMPK, phospho-AMP-activated protein kinase; TCF11/Nrf1, transcription factor 11/Nuc
Neurosteroid allopregnanolone attenuates cognitive dysfunctions in 6-OHDA-induced rat model of Parkinson’s disease
Keywords: 6-OHDA، 6-hydroxydopamine; PD, Parkinson’s disease; Allo, allopregnanolone; 6-OHDA, 6-hydroxydopamine; MWM, Moris water maze; NOR, novel object recognition; TH, thyrosin hydroxylase; SGZ, hippocampal subgranular zone; MPTP, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine; EGF, epid
Hydroxytyrosol induces phase II detoxifying enzyme expression and effectively protects dopaminergic cells against dopamine- and 6-hydroxydopamine induced cytotoxicity
Keywords: 6-OHDA، 6-hydroxydopamine; Hydroxytyrosol; Parkinson's disease; Dopamine; Oxidative stressPD, Parkinson's disease; DA, Dopamine; DAQ, Dopamine quinone; HT, Hydroxytyrosol; SF, Sulforaphane; 6-OHDA, 6-Hydroxydopamine; MPP+, 1-Methyl-4-phenylpyridinium; ROS, Reactive oxygen species;
Overexpression of α-synuclein simultaneously increases glutamate NMDA receptor phosphorylation and reduces glucocerebrosidase activity
Keywords: 6-OHDA، 6-hydroxydopamine; α-syn, α-synuclein; CMA, chaperone-mediated autophagy; GBA, glucosidase beta acid; GCase, glucocerebrosidase; GFP, green fluorescent protein; NMDAR, N-methyl-d-aspartate receptor; 6-OHDA, 6-hydroxydopamine; PD, Parkinson’s disease; TH, tyrosine hydroxylas
Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; CNS, central nervous system; CSF, cerebrospinal fluid; IGF-1, insulin-like growth factor-1; IR, insulin receptor; METH, methamphetamine; NTFs, neurotrophic factors; PD, Parkinson’s disease; PFA, paraformaldehyde; SN, substantia
Striatal mRNA expression patterns underlying peak dose l-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; AIM, abnormal involuntary movements; ANOVA, analysis of variance; LTP, long term potentiation; PD, Parkinson’s disease; SNc, substantia nigra pars compactaRNA-seq; dyskinesia; 6-OHDA; l-DOPA; striatum; Parkinson’s disease
l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; AADC, aromatic amino acid decarboxylase; AIM, abnormal involuntary movements; ANOVA, Analysis of Variance; DA, dopamine; ISH, in situ hybridization; l-DOPA, l-3,4-Dihydroxyphenylalanine; LID, l-DOPA-induced dyskinesia; mfb, medi
New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders
Keywords: 6-OHDA، 6-hydroxydopamine; 5-HT receptors; mRNA editing; G protein coupled receptors; Receptor oligomers; Dopamine; GABA5-HT2C receptor, serotonin2C receptor; DRN, dorsal raphe nucleus; MRN, medial raphe nucleus; DA, Dopamine; 6-OHDA, 6-hydroxydopamine; MPTP, 1-methyl-4-phenyl-1,2,
MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; ADTN, 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene; DA, dopamine; EPS, extrapyrimidal side effects; HP, haloperidol; IP, intraperitoneally; MIF-1, melanocyte-stimulating hormone release inhibiting factor-1; MPTP, 1-methyl
Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: A longitudinal in-vivo study
Keywords: 6-OHDA، 6-hydroxydopamine; 3-D, three-dimensional; 6-OHDA, 6-hydroxydopamine; 11C-CH3I, carbon-11 labeled methyliodide; 11C-DTBZ, carbon-11 labeled dihydrotetrabenazine; ANOVA, analysis of variance; BR, binding ratio; DA, dopamine; DAT, dopamine transporter; DMSO, dimethyl sulfoxid
Suppression effects of O-demethyldemethoxycurcumin on thapsigargin triggered on endoplasmic reticulum stress in SK-N-SH cells
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; AD, Alzheimer's disease; ATF6, activating transcription factor 6; BiP, binding immunoglobulin protein; BSA, bovine serum albumin; CHOP, C/EBP homologous protein; CNS, central nervous system; DMSO, dimethyl sulfoxide; DNA, deoxyr
Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine–induced Parkinson's disease rats
Keywords: 6-OHDA، 6-hydroxydopamine; β-AR, β-adrenoceptor; DA, dopamine; DAT, dopamine transporter; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GI, gastrointestinal; 5-HT, 5-hydroxytryptamine; IR, immunoreactive; NE, norepinephrine; 6-OHDA, 6-hydroxydopamine; PD, Parkinson's disease; SN
Serotonergic interaction between medial prefrontal cortex and mesotelencephalic DA system underlies cognitive and affective deficits in hemiparkinsonian rats
Keywords: 6-OHDA، 6-hydroxydopamine; 5,7-DHT, 5,7-dihydroxytryptamine; 5-HIAA, 5-hydroxyindoleacetic acid; 6-OHDA, 6-hydroxydopamine; DA, dopamine; dmPFC, dorsal mPFC; DOPAC, 3,4-dihydroxyphenylacetic acid; dSTR, dorsal striatum; EPM, elevated plus maze; FST, forced swim test; MDS, midbrain
Characterization of nociceptive response to chemical, mechanical, and thermal stimuli in adolescent rats with neonatal dopamine depletion
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; ADHD, attention-deficit hyperactivity disorder; ANOVA, analysis of variance; Fos-ir, c-Fos-immunoreactivity; LC, locus coeruleus; MAP, methamphetamine; SN, substantia nigra; TH, tyrosine hydroxylase; VTA, ventral tegmental arean
Loss of Nogo-A-expressing neurons in a rat model of Parkinson’s disease
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; ANOVA, analysis of variance; CB, calbindin; ChAT, choline acetyltransferase; CNS, central nervous system; CR, calretinin; DA, dopamine; DAB, diaminobenzidine; FG, fluorogold; GABA, γ-aminobutyric acid; GFAP, glial fibrillary aci
Giant GABAA receptor mediated currents in the striatum, a common signature of Parkinson's disease in pharmacological and genetic rodent models
Keywords: 6-OHDA، 6-hydroxydopamine; FS, fast spiking interneuron; HFS, high frequency stimulation; LTS, low threshold spiking interneuron; MSN, medium spiny neuron; PINK 1, PTEN-induced putative kinase 1; 6-OHDA, 6-hydroxydopamine; STN, subthalamic nucleus; TAN, tonically active neuronGABA;
Decreased ipsilateral [123I]iododexetimide binding to cortical muscarinic receptors in unilaterally 6-hydroxydopamine lesioned rats
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; ACh, Acetylcholine; AChEI, Acetylcholinesterase inhibitor; AD, Alzheimer’s dementia; DLB, Dementia with Lewy bodies; HC-3, Hemicholinium-3; MFB, Medial forebrain bundle; NBM, Basal nucleus of Meynert; PD, Parkinson’s disease; PD
Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; the ADAGIO study, the Attenuation of Disease Progression with Azilect Given Once-daily) study; CBZ, carbamazepine; curcumin, (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; the DATATOP Study, the Deprenyl an
Upregulation of β1-adrenoceptors is involved in the formation of gastric dysmotility in the 6-hydroxydopamine rat model of Parkinson's disease
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; β-AR, β-adrenoceptor; cDNA, complementary DNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GE, gastric emptying; GI, gastrointestinal; IC50, half maximal inhibitory concentration; IR, immunoreactivity; mRNA, messenger RNA;
Activation of prelimbic 5-HT1A receptors produces antidepressant-like effects in a unilateral rat model of Parkinson’s disease
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; ANOVA, analysis of variance; DA, dopamine; EAAC1-ir, EAAC1-immunoreactive; FST, forced swim test; MFB, medial forebrain bundle; mPFC, medial prefrontal cortex; PD, Parkinson’s disease; PrL, prelimbic; SNc, substantia nigra pars
Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinson׳s disease
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; PD, Parkinson׳s disease; 6-MSITC, 6-(methylsulfinyl)hexyl isothiocyanate; TH, tyrosine hydroxylase; SN, substantia nigra; STR, striatum; GSH, glutathione; ROS, reactive oxygen speciesParkinson׳s disease; 6-hydroxydopamine; Neuro
Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson’s disease
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; BBB, blood–brain barrier; BSA, bovine serum albumin; GDNF, glial cell line-derived neurotrophic factor; IOD, integrated optical density; MFB, median forebrain bundle; OVAL, ovalbumin; PBS, phosphate-buffered saline; PD, Parkinso
Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism?
Keywords: 6-OHDA، 6-hydroxydopamine; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; PDE, phosphodiesterase; 6-OHDA, 6-hydroxydopamine; PDE10A, phosphodiesterase 10A; PDE1B, phosphodiesterase 1BParkinson disease; Levodopa dyskinesia; cAMP; cGMP; Phopsphodiesterase
Heterozygous mutations in the FGF8, SHH and nodal/transforming growth factor beta pathways do not confer increased dopaminergic neuron vulnerability—A zebrafish study
Keywords: 6-OHDA، 6-hydroxydopamine; fgf8, fibroblast growth factor 8; shh, sonic hedgehog; PD, Parkinson's disease; MPP+, 1-Methyl-4-phenyl-pyridinium; TGF-β, transforming growth factor beta; 6-OHDA, 6-hydroxydopamine; WISH, whole-mount in situ hybridization; TH, tyrosine hydroxylase; FWD,
5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; AIMs, Abnormal involuntary movements; DA, Dopamine; L-DOPA, L-3,4-dihydroxyphenylalanine; LID, L-DOPA-induced dyskinesia; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD, Partkinson's disease6-OHDA; Dopamine; Serotonin; L
Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; AIMs, abnormal involuntary movements; ANOVA, analysis of variance; cdk5, cyclin-dependent kinase 5; CS, citrate synthase; DARPP-32, dopamine and cAMP-regulated phosphoprotein 32 kDa; DA, dopamine; EDTA, ethylenediaminetetraaceti
Beta oscillations in the cortico-basal ganglia loop during parkinsonism
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; BBO, beta band oscillations; CBG, cortico-basal ganglia; DBS, deep brain stimulation; GPe, globus pallidus externus; GPi, globus pallidus internus; LFP, local field potential; MPTP, 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine;
Adaptive gene expression changes on the healthy side of parkinsonian rats
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; D1R, D1-class dopamine receptor; D2R, D2-class dopamine receptor; DAT, dopamine transporter; DYN, dynorphin; ENK, enkephalin; GABA, γ-aminobutyric acid; M1, primary motor cortex; MFB, medial forebrain bundle; NR, NMDA glutamater
Delayed administration of zingerone mitigates the behavioral and histological alteration via repression of oxidative stress and intrinsic programmed cell death in focal transient ischemic rats
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; ANOVA, Analysis of variance; Apaf-1, Apoptotic protease activating factor-1; ATP, Adenosine triphosphate; b.wt, Body weight; Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma-2; BSA, Bovine serum albumin; caspase, Cysteine
GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; DA, dopamine; DBS, deep brain stimulation; DOPAC, 3,4-dihydroxyphenylacetic acid; GABA, γ-aminobutyric acid; GPe, globus pallidus externa; GPi, globus pallidus interna; HPLC-EC, high performance liqiuid chromatography with coupl
Axon degeneration in Parkinson's disease
Keywords: 6-OHDA، 6-hydroxydopamine; [3H]TBZOH, tritiated α-dihydrotetrabenazine; 6-OHDA, 6-hydroxydopamine; AAV, adeno-associated virus; AD, Alzheimer's disease; AVs, autophagic vacuoles; DLB, dementia with Lewy Bodies; ILB, incidental Lewy bodies; LB, Lewy body; LRRK2, leucine rich repeat
α4β2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats
Keywords: 6-OHDA، 6-hydroxydopamine; Dyskinesia; l-dopa; Nicotine; Nicotinic; Parkinson's disease; SazetidineAIMs, abnormal involuntary movements; ANOVA, analysis of variance; nAChRs, nicotinic receptors; CNS, central nervous system; α-CtxMII, α-conotoxinMII; 6-OHDA, 6-hydroxydopamine; 125I-
Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: The effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; CV, cresyl violet; NADPH-d, nicotinamide dinucleotide phosphate diaphorase; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; MFB, medial forebrain bundle; mol, molsidomine; PD, Parkinson's disease; SNc, substantia nigra p
Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor
Keywords: 6-OHDA، 6-hydroxydopamine; DA, dopamine; ELISA, enzyme linked immunosorbent assay; GDNF, glial cell lined-derived neurotrophic factor; GFAP, glial fibrillary acidic protein; 6-OHDA, 6-hydroxydopamine; IL-1b, interleukin 1 beta; IL-1ra, interleukin 1 receptor antagonist; iNOS, induc
Amphetamine-induced rotation and l-DOPA-induced dyskinesia in the rat 6-OHDA model: A correlation study
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; AIMs, abnormal involuntary movements; KPBS, potassium phosphate buffered saline; LID, L-DOPA-induced dyskinesia; MFB, medial forebrain bundle; PBS, phosphate buffered saline; PD, Parkinson's disease; SERT, serotonin transporter;
Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain
Keywords: 6-OHDA، 6-hydroxydopamine; 3-OMD, 3-methoxy-4-hydroxy-l-phenylalanine; 5-HT, serotonin; 5,7-DHT, 5,7-dihydroxytryptamine; 6-OHDA, 6-hydroxydopamine; AADC, aromatic l-amino acid decarboxylase; AAV, adeno-associated virus; BBB, blood–brain barrier; BH4, 5,6,7,8-tetrahydro-l-biopterin
Proteomic analysis reveals a protective role for DJ-1 during 6-hydroxydopamine-induced cell death
Keywords: 6-OHDA، 6-hydroxydopamine; 6-OHDA, 6-hydroxydopamine; ROS, reactive oxygen species; PD, Parkinson’s disease; SOD3, extracellular superoxide dismutase; 2-DE, 2-dimensional electrophoresis; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; PYGB, glycogen phosphor
Portable microstimulator for chronic deep brain stimulation in freely moving rats
Keywords: 6-OHDA، 6-hydroxydopamine; DBS, deep brain stimulation; 6-OHDA, 6-hydroxydopamine; ODs, optical densities; PD, Parkinson's disease; STN, subthalamic nucleusImplantable device; High frequency stimulation; Electrode; Parkinson's disease; Rodent; Subthalamic nucleus
Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease
Keywords: 6-OHDA، 6-hydroxydopamine; MAO-B, monoamine oxidase-B; PPAR, peroxisome proliferator-activated receptor; SNc, substantia nigra pars compacta; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 6-OHDA, 6-hydroxydopamine; VTA, ventral tegmental area; TH, tyrosine hydroxylasePPAR; Pi
Full and partial peroxisome proliferation-activated receptor-gamma agonists, but not delta agonist, rescue of dopaminergic neurons in the 6-OHDA Parkinsonian model is associated with inhibition of microglial activation and MMP expression
Keywords: 6-OHDA، 6-hydroxydopamine; HPLC-ECD, High performance liquid chromatography-Electrochemical detection; 6-OHDA, 6-hydroxydopamine; mfb, medial forebrain bundle; PD, Parkinson's disease; SNc, substantia nigra pars compacta; PPAR, Peroxisome proliferator-activated receptor; MMP, matri